Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (EW)
NYSE:EW
Earnings Data
Report Date
Apr 29, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.73Last Year’s EPS
0.64Same Quarter Last Year
Moderate Buy
Based on 21 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveys a broadly positive outlook: the company delivered strong top‑line growth (Q4 +11.6%, FY +10.7%), robust TAVR and TMTT momentum, and reiterated confident 2026 guidance (8%–10% sales growth; EPS $2.90–$3.05). Key positives include compelling long‑term clinical evidence, successful product launches (SAPIEN M3, NextGen PASCAL), margin discipline and a healthy balance sheet. Near‑term headwinds are primarily deliberate investments in patient access and field resources (driving higher SG&A), one‑time GAAP charges (GennaValve/litigation), an elevated tax rate in the quarter, and distributor inventory adjustments that modestly impacted surgical sales. Management frames the incremental spending as strategic and expects margin expansion over time. Overall, the positive operational and strategic catalysts outweigh the one‑time and timing‑related negatives.Company Guidance
Strong Q4 and Full-Year Sales Growth
Total sales of $1.57 billion in Q4, up 11.6% year‑over‑year; full‑year 2025 sales growth of 10.7% — demonstrating broad-based demand and momentum entering 2026.
TAVR Performance and Clinical Momentum
TAVR Q4 global sales of $1.16 billion, up 10.6% year‑over‑year; overall procedural growth in the quarter remained in the high single digits. Strength supported by seven‑year PARTNER 3 and ten‑year PARTNER 2 durability data, Early TAVR evidence (including asymptomatic indication), strong SAPIEN 3 Ultra Resilia adoption, and supportive Europe guideline changes — all cited as durable growth catalysts.
TMTT Segment Surge
TMTT grew over 40% in Q4 to $156 million; full‑year TMTT sales exceeded $500 million. Growth driven by PASCAL and EVOQUE adoption, FDA approval and initial launch of SAPIEN M3, NextGen PASCAL rollout, and expected contribution toward a $2 billion TMTT revenue target by 2030.
Surgical Business Milestones
Surgical Q4 sales of $254 million, up 2% year‑over‑year; full‑year surgical sales grew 4.3% and exceeded $1 billion for the first time. Positive MOMENTYS one‑year data (100% freedom from SVD) and planned initial introduction of surgical LAAC later this year provide new product and clinical catalysts.
Profitability and Margin Discipline
Q4 adjusted gross profit margin of 78.3% (vs. 79% year‑ago) and Q4 adjusted operating profit margin of 23.7%; full‑year 2025 adjusted operating margin of 27%. Company expects full‑year 2026 adjusted gross margin to be ~78%–79% and forecasted ~150 basis points of constant‑currency operating margin expansion in 2026.
Strong Balance Sheet and Capital Return
Approximately $3 billion in cash and cash equivalents as of Dec 31, 2025; repurchased just under $900 million of stock in 2025 (including ~$40 million in Q4) and ~ $2 billion of share repurchase authorization remaining.
Confident 2026 Guidance and Near‑Term Outlook
Management expressed increased confidence in meeting 2026 sales growth guidance of 8%–10% and EPS guidance of $2.90–$3.05. Q1 2026 sales guidance of $1.55 billion–$1.63 billion and Q1 adjusted EPS guidance of $0.70–$0.76; FX expected to provide ~ $40 million upside to full‑year 2026 sales at current rates.
Patient Access & Clinical Engagement Initiatives
Increased investments in patient access initiatives, including partnership with the American Heart Association Heart Valve initiative, European guideline dissemination efforts, and field force reinforcement — aimed at driving earlier, guideline‑based treatment and expanding addressable market.
EW Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
EW Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 10, 2026 | $77.05 | $79.33 | +2.96% |
Oct 30, 2025 | $83.48 | $82.45 | -1.23% |
Jul 24, 2025 | $75.80 | $80.00 | +5.54% |
Apr 23, 2025 | $70.46 | $75.13 | +6.63% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Edwards Lifesciences (EW) report earnings?
Edwards Lifesciences (EW) is schdueled to report earning on Apr 29, 2026, After Close (Confirmed).
What is Edwards Lifesciences (EW) earnings time?
Edwards Lifesciences (EW) earnings time is at Apr 29, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EW EPS forecast?
EW EPS forecast for the fiscal quarter 2026 (Q1) is 0.73.